Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration.
Feras M GhazawiMegan M LimJan P DutzMark G KirchhofPublished in: International journal of dermatology (2020)
Recommendations were made recently to limit or stop the use of oral and systemic immunotherapies for skin diseases due to potential risks to the patients during the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19 pandemic. Herein, we attempt to identify potentially safe immunotherapies that may be used in the treatment of cutaneous diseases during the current COVID-19 pandemic. We performed a literature review to approximate the risk of SARS-CoV-2 infection, including available data on the roles of relevant cytokines, cell subsets, and their mediators in eliciting an optimal immune response against respiratory viruses in murine gene deletion models and humans with congenital deficiencies were reviewed for viral infections risk and if possible coronaviruses specifically. Furthermore, reported risk of infections of biologic and non-biologic therapeutics for skin diseases from clinical trials and drug data registries were evaluated. Many of the immunotherapies used in dermatology have data to support their safe use during the COVID-19 pandemic including the biologics that target IgE, IL-4/13, TNF-α, IL-17, IL-12, and IL-23. Furthermore, we provide evidence to show that oral immunosuppressive medications such as methotrexate and cyclosporine do not significantly increase the risk to patients. Most biologic and conventional immunotherapies, based on doses and indications in dermatology, do not appear to increase risk of viral susceptibility and are most likely safe for use during the COVID-19 pandemic. The limitation of this study is availability of data on COVID-19.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- rheumatoid arthritis
- end stage renal disease
- clinical trial
- electronic health record
- immune response
- ejection fraction
- newly diagnosed
- coronavirus disease
- big data
- chronic kidney disease
- prognostic factors
- single cell
- gene expression
- human health
- randomized controlled trial
- peritoneal dialysis
- high dose
- dendritic cells
- wound healing
- soft tissue
- data analysis
- bone marrow
- mesenchymal stem cells
- deep learning
- dna methylation
- transcription factor
- phase ii